Arrowhead Pharmaceuticals (STU:HDP1) ROCE % : -66.04% (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Arrowhead Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2024 was -66.04%.

Arrowhead Pharmaceuticals ROCE % Historical Data

The historical data trend for Arrowhead Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals ROCE % Chart

Arrowhead Pharmaceuticals Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

ROCE %

Get a 7-Day Free Trial

35.32

-24.77

-26.96

-33.62

-29.96

Arrowhead Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															26.67	-51.05	-60.36	-86.22	-66.04

Arrowhead Pharmaceuticals ROCE % Calculation

Arrowhead Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2023 )		(A: Sep. 2022 )		(A: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2023 )		(A: Sep. 2022 )		(A: Sep. 2023 )
	=	-176.311	/	( ( (698.858 - 140.239)	+	(717.322 - 98.812) )	/ 2 )
	=	-176.311	/	( (558.619	+	618.51)	/ 2 )
	=	-176.311	/	588.5645
	=	-29.96 %

Arrowhead Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-440.688	/	( ( (574.304 - 58.434)	+	(878.738 - 59.961) )	/ 2 )
	=	-440.688	/	( ( 515.87	+	818.777 )	/ 2 )
	=	-440.688	/	667.3235
	=	-66.04 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Arrowhead Pharmaceuticals (STU:HDP1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Arrowhead Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arrowhead Pharmaceuticals (STU:HDP1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (STU:HDP1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ARWR:USA

Address

177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105

Website

https://www.arrowheadpharma.com

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Arrowhead Pharmaceuticals (STU:HDP1) Headlines

No Headlines